Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in the USA / NCT07197775
Enrolling by invitation Observational

Post-market SUrveiLlance RegiStry for the Endogenex System (Endogenex PULSE Registry)

NCT07197775 · tracked via the Priya Life Science USA tracker
Sponsor
Endogenex, Inc
Phase
Observational
Started
2026-03-11
Last updated
2026-07-01

Condition(s) studied

Type 2 Diabetes Mellitus (T2DM)Type2DiabetesDiabetes Mellitus, Type 2Type 2 DiabetesDiabetes

Study summary

This registry is designed to collect long-term data and support ongoing post-market surveillance of real-world data for the Endogenex System.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Type 2 diabetes * Have been treated with the Endogenex System * Consented to participate in the Endogenex PULSE Registry Exclusion Criteria: * Unwilling or unable to attend study visits * Unwilling or unable to provide medical records to study sites

Primary outcome measure(s)

  • Incidence of adverse events — Through 5 years
    Incidence of device-related and/or procedure-related adverse events

Trial sites (4)

FacilityCityRegionStatus
Care Access Quincy Massachusetts
Care Access Raleigh North Carolina
Care Access Houston Texas
St Vincent's Hospital Melbourne Fitzroy Victoria

More Endogenex, Inc. trials in the USA

Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes Active, not recruiting
Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study Enrolling by invitation

Other trials for the same condition

Evaluation of MiniMed Next Generation Extended Wear Sensors and Algorithm in Patients With Type 1 and Type 2 Diabetes Recruiting
Mathematical Modeling of Blood Sugar and Hormone Responses in Insulin-Dependent Type 2 Diabetes Recruiting
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes Active, not recruiting
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) Recruiting
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07197775 on ClinicalTrials.gov ↗ ← All trials in the USA